DCF Advisers’s Prothena PRTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
– Sell
-52,500
Closed -$3.18M – 81
2022
Q3
$3.18M Buy
+52,500
New +$1.66M 2.06% 14
2022
Q2
– Sell
-2,500
Closed -$91K – 84
2022
Q1
$91K Buy
+2,500
New +$90.1K 0.04% 64

Other funds holding PRTA

DCF Advisers's PRTA Position: Q3 2026 in Review

DCF Advisers increased its Prothena (PRTA) stake by 77% in Q3 2026, buying an estimated $506K and bringing the position to 129,911 shares worth $1.09M. The position accounts for 0.25% of the portfolio, ranked #65.

DCF Advisers first reported a position in PRTA in Q1 2021 and has held it in 23 quarters since. The position peaked at $5.79M in Q2 2023. 182 funds tracked by Wall St. Rank hold PRTA as of Q3 2026.

  • DCF Advisers held 129,911 shares of Prothena worth $1.09M as of Q3 2026.
  • DCF Advisers bought 56,664 Prothena shares in Q3 2026, an estimated $506K.
  • Prothena made up 0.25% of DCF Advisers's portfolio in Q3 2026, its #65 holding.
  • DCF Advisers first reported a position in Prothena in Q1 2021 and has held it in 23 quarters since.
  • DCF Advisers's Prothena position peaked at $5.79M in Q2 2023.
  • 182 funds tracked by Wall St. Rank held Prothena as of Q3 2026.

Based on DCF Advisers's 13F filing for Q3 2026, filed 4 Nov 2026.